StandlE, SchnellO, McGuireDK, et al.: Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol, 2017; 8587:1–12.
2.
Rodriguez-GutierrezR, LipskaKJ, McCoyRG, et al.: Hypoglycemia as an indicator of good diabetes care. BMJ, 2016; 352:i1084.
3.
Rodríguez-GutiérrezR, MontoriVM: Glycemic control for patients with type 2 diabetes mellitus- our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes, 2016; 9:504–512.
4.
Standards of medical care in diabetes—2007. Diabetes Care, 2007; 30:S4–S41.
HemmingsenB, LundSS, GluudC, et al.: Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ, 2011; 343(nov24 1):d6898.
7.
BoussageonR, Bejan-AngoulvantT, Saadatian-ElahiM, et al.: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 2011; 343:d4169.
8.
CocaSG, Ismail-BeigiF, HaqN, et al.: Role of intensive glucose control in development of renal endpoints in type 2 diabetes: systematic review and meta- analysis. Arch Intern Med, 2012; 172:761–769.
9.
McCormackJ, GreenhalghT: Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ, 2000; 320:1720–1723.
10.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352:837–853.
11.
GersteinHC, MillerME, BryngtonRP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
12.
ADVANCE Collaborative Group; PatelA, MacMahonS, ChalmersJ, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008:358:2560–2572.
13.
DuckworthW, AbrairaC, MoritzT, et al.Glucose control and vascular complications in veterans with type 2 diabetes. New Engl J Med, 2009; 360:129–139.
14.
HolmanRR, PaulSK, BethelMA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359:1577–1589.
15.
GersteinHC, MillerME, GenuthS, et al.: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med, 2011; 364:818–828.
16.
ZinmanB, WannerC, LachinJM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373:2117–2128.
17.
EliaschewitzFG, JódarE, LeiterLA, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016; 375:1834–1844.
18.
MarsoSP, DanielsGH, Brown-FrandsenK, et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375:11–22.
19.
RysP, WojciechowskiP, Rogoz-SitekA, et al.: Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol, 2015; 52:649–662.
20.
FreemantleN, ChouE, FroisC, et al.: Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open, 2016; 6:e009421.
21.
AjjanRA: How can we realize the clinical benefits of continuous glucose monitoring?. Diabetes Technol Ther, 2017; 19(S2):S27–S36.
22.
CarlsonAL, MullenDM, BergenstalRM: Clinical use of continuous glucose monitoring in adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19(S2):S55–S61.
23.
VigerskyR, ShrivastavaM: Role of continuous glucose monitoring for type 2 in diabetes management and research. J Diabetes Complications, 2017; 31:280–287.
24.
NathanDM, BuseJB, KahnSE, et al.: Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care, 2013; 36:2254–2261.
25.
InzucchiSE, BergenstalRM, BuseJB, et al.: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012; 35:1364–1379.
26.
BarnettK, MercerSW, NorburyM, et al.: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet, 2012; 380:37–43.
27.
Rodriguez-GutierrezR, GionfriddoMR, Singh OspinaN, et al.: Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol, 2016; 4:706–716.
